Jason D Wright1, Stephanie Cham2, Ling Chen3, William M Burke4, June Y Hou4, Ana I Tergas5, Vrunda Desai6, Jim C Hu7, Cande V Ananth8, Alfred I Neugut5, Dawn L Hershman9. 1. Herbert Irving Comprehensive Cancer Center of the College of Physicians and Surgeons, Columbia University, New York, NY; College of Physicians and Surgeons, Columbia University, New York, NY; New York Presbyterian Hospital, New York, NY. Electronic address: jw2459@columbia.edu. 2. College of Physicians and Surgeons, Columbia University, New York, NY; New York Presbyterian Hospital, New York, NY. 3. College of Physicians and Surgeons, Columbia University, New York, NY. 4. Herbert Irving Comprehensive Cancer Center of the College of Physicians and Surgeons, Columbia University, New York, NY; College of Physicians and Surgeons, Columbia University, New York, NY; New York Presbyterian Hospital, New York, NY. 5. Herbert Irving Comprehensive Cancer Center of the College of Physicians and Surgeons, Columbia University, New York, NY; College of Physicians and Surgeons, Columbia University, New York, NY; Joseph L. Mailman School of Public Health, Columbia University, New York, NY; New York Presbyterian Hospital, New York, NY. 6. Yale University, New Haven, CT. 7. Weill Cornell Medical College, New York, NY; New York Presbyterian Hospital, New York, NY. 8. College of Physicians and Surgeons, Columbia University, New York, NY; Joseph L. Mailman School of Public Health, Columbia University, New York, NY. 9. Herbert Irving Comprehensive Cancer Center of the College of Physicians and Surgeons, Columbia University, New York, NY; College of Physicians and Surgeons, Columbia University, New York, NY; Joseph L. Mailman School of Public Health, Columbia University, New York, NY; New York Presbyterian Hospital, New York, NY; Yale University, New Haven, CT.
Abstract
BACKGROUND: To limit the potential short and long-term morbidity of lymphadenectomy, sentinel lymph node biopsy has been proposed for endometrial cancer. The principle of sentinel lymph node biopsy relies on removal of a small number of lymph nodes that are the first drainage basins from a tumor and thus the most likely to harbor tumor cells. While the procedure may reduce morbidity, efficacy data are limited and little is known about how commonly the procedure is performed. OBJECTIVE: We examined the patterns and predictors of use of sentinel lymph node biopsy and outcomes of the procedure in women with endometrial cancer who underwent hysterectomy. STUDY DESIGN: We used the Perspective database to identify women with uterine cancer who underwent hysterectomy from 2011 through 2015. Billing and charge codes were used to classify women as having undergone lymphadenectomy, sentinel lymph node biopsy, or no nodal assessment. Multivariable models were used to examine clinical, demographic, and hospital characteristics with use of sentinel lymph node biopsy. Length of stay and cost were compared among the different methods of nodal assessment. RESULTS: Among 28,362 patients, 9327 (32.9%) did not undergo nodal assessment, 17,669 (62.3%) underwent lymphadenectomy, and 1366 (4.8%) underwent sentinel lymph node biopsy. Sentinel lymph node biopsy was performed in 1.3% (95% confidence interval, 1.0-1.6%) of abdominal hysterectomies, 3.4% (95% confidence interval, 2.7-4.1%) of laparoscopic hysterectomies, and 7.5% (95% confidence interval, 7.0-8.0%) of robotic-assisted hysterectomies. In a multivariable model, more recent year of surgery was associated with performance of sentinel lymph node biopsy. Compared to abdominal hysterectomy, those undergoing laparoscopic (adjusted risk ratio, 2.45; 95% confidence interval, 1.89-3.18) and robotic-assisted (adjusted risk ratio, 2.69; 95% confidence interval, 2.19-3.30) hysterectomy were more likely to undergo sentinel lymph node biopsy. Among women who underwent minimally invasive hysterectomy, length of stay and cost were lower for sentinel lymph node biopsy compared to lymphadenectomy. CONCLUSION: The use of sentinel lymph node biopsy for endometrial cancer increased from 2011 through 2015. The increased use was most notable in women who underwent a robotic-assisted hysterectomy.
BACKGROUND: To limit the potential short and long-term morbidity of lymphadenectomy, sentinel lymph node biopsy has been proposed for endometrial cancer. The principle of sentinel lymph node biopsy relies on removal of a small number of lymph nodes that are the first drainage basins from a tumor and thus the most likely to harbor tumor cells. While the procedure may reduce morbidity, efficacy data are limited and little is known about how commonly the procedure is performed. OBJECTIVE: We examined the patterns and predictors of use of sentinel lymph node biopsy and outcomes of the procedure in women with endometrial cancer who underwent hysterectomy. STUDY DESIGN: We used the Perspective database to identify women with uterine cancer who underwent hysterectomy from 2011 through 2015. Billing and charge codes were used to classify women as having undergone lymphadenectomy, sentinel lymph node biopsy, or no nodal assessment. Multivariable models were used to examine clinical, demographic, and hospital characteristics with use of sentinel lymph node biopsy. Length of stay and cost were compared among the different methods of nodal assessment. RESULTS: Among 28,362 patients, 9327 (32.9%) did not undergo nodal assessment, 17,669 (62.3%) underwent lymphadenectomy, and 1366 (4.8%) underwent sentinel lymph node biopsy. Sentinel lymph node biopsy was performed in 1.3% (95% confidence interval, 1.0-1.6%) of abdominal hysterectomies, 3.4% (95% confidence interval, 2.7-4.1%) of laparoscopic hysterectomies, and 7.5% (95% confidence interval, 7.0-8.0%) of robotic-assisted hysterectomies. In a multivariable model, more recent year of surgery was associated with performance of sentinel lymph node biopsy. Compared to abdominal hysterectomy, those undergoing laparoscopic (adjusted risk ratio, 2.45; 95% confidence interval, 1.89-3.18) and robotic-assisted (adjusted risk ratio, 2.69; 95% confidence interval, 2.19-3.30) hysterectomy were more likely to undergo sentinel lymph node biopsy. Among women who underwent minimally invasive hysterectomy, length of stay and cost were lower for sentinel lymph node biopsy compared to lymphadenectomy. CONCLUSION: The use of sentinel lymph node biopsy for endometrial cancer increased from 2011 through 2015. The increased use was most notable in women who underwent a robotic-assisted hysterectomy.
Authors: J How; W H Gotlieb; J Z Press; J Abitbol; M Pelmus; A Ferenczy; S Probst; R Gotlieb; S Brin; S Lau Journal: Gynecol Oncol Date: 2015-04-12 Impact factor: 5.482
Authors: Beatrice Cormier; Alexandre T Rozenholc; Walter Gotlieb; Marie Plante; Christopher Giede Journal: Gynecol Oncol Date: 2015-06-03 Impact factor: 5.482
Authors: Charu Sharma; Israel Deutsch; Sharyn N Lewin; William M Burke; Yaming Qiao; Xuming Sun; Clifford K Chao; Thomas J Herzog; Jason D Wright Journal: Am J Obstet Gynecol Date: 2011-09-16 Impact factor: 8.661
Authors: Jason D Wright; Cande V Ananth; Sharyn N Lewin; William M Burke; Yu-Shiang Lu; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman Journal: JAMA Date: 2013-02-20 Impact factor: 56.272
Authors: Maria B Schiavone; Thomas J Herzog; Cande V Ananth; Elizabeth T Wilde; Sharyn N Lewin; William M Burke; Yu-Shiang Lu; Alfred I Neugut; Dawn L Hershman; Jason D Wright Journal: Am J Obstet Gynecol Date: 2012-09-17 Impact factor: 8.661
Authors: Christine H Kim; Robert A Soslow; Kay J Park; Emma L Barber; Fady Khoury-Collado; Joyce N Barlin; Yukio Sonoda; Martee L Hensley; Richard R Barakat; Nadeem R Abu-Rustum Journal: Int J Gynecol Cancer Date: 2013-06 Impact factor: 3.437
Authors: Andrea Papadia; Maria Luisa Gasparri; Alessandro Buda; Michael D Mueller Journal: J Cancer Res Clin Oncol Date: 2017-08-21 Impact factor: 4.553
Authors: Natalia R Gómez-Hidalgo; Ling Chen; June Y Hou; Ana I Tergas; Caryn M St Clair; Cande V Ananth; Dawn L Hershman; Jason D Wright Journal: Cancer Invest Date: 2018-03-22 Impact factor: 2.176
Authors: Luigi Della Corte; Pierluigi Giampaolino; Antonio Mercorio; Gaetano Riemma; Antonio Schiattarella; Pasquale De Franciscis; Giuseppe Bifulco Journal: Transl Cancer Res Date: 2020-12 Impact factor: 1.241